DRRX vs. EYEN, FBIO, JAGX, VYNE, CARA, NRXP, UNCY, CASI, LEXX, and HCWB
Should you be buying DURECT stock or one of its competitors? The main competitors of DURECT include Eyenovia (EYEN), Fortress Biotech (FBIO), Jaguar Health (JAGX), VYNE Therapeutics (VYNE), Cara Therapeutics (CARA), NRx Pharmaceuticals (NRXP), Unicycive Therapeutics (UNCY), CASI Pharmaceuticals (CASI), Lexaria Bioscience (LEXX), and HCW Biologics (HCWB). These companies are all part of the "pharmaceutical preparations" industry.
Eyenovia (NASDAQ:EYEN) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, community ranking, dividends and media sentiment.
25.8% of Eyenovia shares are held by institutional investors. Comparatively, 28.0% of DURECT shares are held by institutional investors. 7.1% of Eyenovia shares are held by insiders. Comparatively, 4.3% of DURECT shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Eyenovia presently has a consensus price target of $10.00, suggesting a potential upside of 1,326.53%. DURECT has a consensus price target of $27.50, suggesting a potential upside of 2,056.86%. Given Eyenovia's higher possible upside, analysts plainly believe DURECT is more favorable than Eyenovia.
Eyenovia has a net margin of 0.00% compared to Eyenovia's net margin of -279.77%. DURECT's return on equity of -322.68% beat Eyenovia's return on equity.
Eyenovia has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500. Comparatively, DURECT has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500.
DURECT received 146 more outperform votes than Eyenovia when rated by MarketBeat users. Likewise, 65.15% of users gave DURECT an outperform vote while only 65.13% of users gave Eyenovia an outperform vote.
In the previous week, Eyenovia and Eyenovia both had 4 articles in the media. DURECT's average media sentiment score of 0.64 beat Eyenovia's score of 0.48 indicating that Eyenovia is being referred to more favorably in the media.
Eyenovia has higher earnings, but lower revenue than DURECT. DURECT is trading at a lower price-to-earnings ratio than Eyenovia, indicating that it is currently the more affordable of the two stocks.
Summary
Eyenovia beats DURECT on 9 of the 15 factors compared between the two stocks.
Get DURECT News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DRRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
